Almut Heinken

1 week ago | sciencedirect.com | Giovanni Rigoni |Maria Soriano |Almut Heinken |Ines Thiele

In recent years, the treatment of inflammatory bowel disease (IBD) has undergone revolutionary changes with the emergence of therapies that block the action of inflammatory cytokines, represented by infliximab and ustekinumab (UST).1 UST was approved for the treatment of Crohn’s disease (CD) in the United States and the European Union in 2016, and in China in 2020.2 Up to now, a substantial amount of prospective and retrospective studies around the world have confirmed the effectiveness of...